Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWP-102 in advanced malignancies
NCT05024305Phase 1Unknown
- Sponsor
- Therawisdom Biopharma
- Start
- Mar 2022
- Primary completion
- Dec 2022
- Modality
- Blood Coagulation Factors
- Countries
- 1
01
Overview
Phase 1, open-label trial of TWP-102 in malignant neoplasms (advanced stage) (2 cohorts), sponsored by Therawisdom Biopharma. Primary endpoints: Incidence of adverse events/serious adverse event related with TWP-102 injection and Dose-limiting toxicity. Status: unknown.
02
Drugs
TWP-102
03
Conditions
malignant neoplasms (advanced stage)
Beyond the preview
Go deeper on NCT05024305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024305.